US Babies Are Being Born With Measles for the First Time in Decades

What Happened

For the first time in decades, babies in the United States are being born with measles, per AP.

The emergence is driven by declining vaccination rates.

When a pregnant woman has no immunity to measles, the virus can reach the baby before birth. Cases at birth are a sign that the disease is circulating widely enough to reach people who cannot be vaccinated yet.

The Wider Picture

US measles cases have passed 5,000 in 2026. The CDC counted 5,182 cases.

The United States also recently lost its measles elimination status, a designation it held for decades.

Elimination status is lost when transmission continues uninterrupted for a year. Regaining it requires stopping sustained spread again.

Newborns are the most exposed group in an outbreak. Infants do not get their first measles shot until around their first birthday, so they depend on the immunity of the people around them.

As vaccination rates fall, that protection weakens, and cases in newborns are one of the results.

Why It Matters

Measles is one of the most contagious diseases known. It spreads through the air and can linger in a room after an infected person leaves.

Most cases recover, but measles can cause pneumonia, brain swelling, and death, with infants at the highest risk.

Health officials have tied the current rise directly to fewer children receiving the measles, mumps, and rubella vaccine on schedule.

Do you want to see how to make more plays? Do you want to find gains yourself? Unusual Whales helps you find market opportunities through our market tide, historical options flow, GEX, and much, much more. Create a free account here to start conquering the market with Unusual Whales

Options and Market Impact

The main listed vaccine makers here are Merck (MRK), which makes the MMR vaccine used in the US, and Pfizer (PFE).

Outbreaks can lift vaccine demand at the margin, as health departments run catch-up campaigns and clinics restock.

For companies the size of Merck and Pfizer, measles vaccine sales are a small part of total revenue, so a direct earnings impact is unlikely to be large.

The bigger market question is policy. A prolonged outbreak raises pressure on federal and state health budgets, and any change in vaccine recommendations or school requirements would matter more for the stocks than the case count itself.

Traders watching the space should follow CDC case updates and any policy statements from federal health officials.

Bottom Line

Babies are being born with measles in the US for the first time in decades because vaccination rates have fallen.

Cases have passed 5,000 this year and the country has lost its elimination status.

For markets, the story runs through vaccine makers and health policy, and both are worth watching as case counts update.

Sign up for Unusual Whales to track the flow: https://unusualwhales.com/login?ref=blubber

Track MRK on Unusual Whales
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.